Wen-Fu Tan (Wenfu Tan)

Publication Activity (10 Years)

Years Active: 2021-2024
Publications (10 Years): 6

Top Topics

Lipopolysaccharide Induced

Immune Response

Top Venues

The American journal of Chinese medicine

Molecular cancer therapeutics

Cell death & disease

This page only lists publications with an associated author ORCID identifier.

Publications

Ying Kong, Xinyue Zhao, Zhaofu Wang, Siqi Yuan, Sheng Chen, Shidi Lou, Shichao Ma, Yunfeng Li, Xinghao Wang, Yangfeng Ge, Guobin Li, Hongbing Yang, Mengxi Zhao, Dandan Li, Hailong Zhang, Wen-Fu Tan, Juan Wang
A Selective FGFR1/2 PROTAC Degrader with Antitumor Activity. Molecular cancer therapeutics (2024)
Xu-Wei Zhou, Juan Wang, Wen-Fu Tan
Apigenin Suppresses Innate Immune Responses and Ameliorates Lipopolysaccharide-Induced Inflammation via Inhibition of STING/IRF3 Pathway. The American journal of Chinese medicine 52 (2) (2024)
Xu-Wei Zhou, Juan Wang, Wen-Fu Tan
Apigenin Suppresses Innate Immune Responses and Ameliorates Lipopolysaccharide-Induced Inflammation via Inhibition of STING/IRF3 Pathway. The American journal of Chinese medicine 52 (2) (2024)
Ying Kong, Xinyue Zhao, Zhaofu Wang, Siqi Yuan, Sheng Chen, Shidi Lou, Shichao Ma, Yunfeng Li, Xinghao Wang, Yangfeng Ge, Guobin Li, Hongbing Yang, Mengxi Zhao, Dandan Li, Hailong Zhang, Wen-Fu Tan, Juan Wang
A selective Fibroblast Growth Factor Receptor 1/2 PROTAC degrader with antitumor activity. Molecular cancer therapeutics (2024)
Xu-Wei Zhou, Juan Wang, Wen-Fu Tan
Apigenin Suppresses Innate Immune Responses and Ameliorates Lipopolysaccharide-Induced Inflammation via Inhibition of STING/IRF3 Pathway. The American journal of Chinese medicine (2024)
Jun Yang, Juan Wang, Yuan Liu, Yu Zhang, Wenjing Huang, Yu Zou, Yanyan Qiu, Weiyang Cai, Jing Gao, Hu Zhou, Ying-Li Wu, Weijun Liu, Qingqing Ding, Yanjie Zhang, Pei-Hao Yin, Wen-Fu Tan
PGE2-JNK signaling axis non-canonically promotes Gli activation by protecting Gli2 from ubiquitin-proteasomal degradation. Cell death & disease 12 (7) (2021)